HOME >> MEDICINE >> NEWS
Cholesterol guidelines can reduce recurrent heart problems

Current cholesterol guidelines can prevent a significant proportion of deaths and recurrent heart attacks in people with existing heart disease, according to researchers at the University of California, San Francisco.

The guidelines, however, can prevent only a modest proportion of first-time heart attacks, the researchers report in the September 1 issue of the Journal of the American College of Cardiology.

Using a computer simulation of 35- to 84-year-old Americans, the researchers measured the projected impact of the National Cholesterol Education Program (NCEP) guidelines between the years 2000 and 2020. They found that people with heart disease can expect to reap greater benefits from lowering their cholesterol levels than people without heart disease, in terms of decreasing heart attacks and heart disease deaths and increasing years of life.

"Many people have assumed that lowering cholesterol levels before the onset of heart disease would have a powerful effect as a primary prevention tool," said Lee Goldman, MD, MPH, FACC, UCSF professor of medicine and lead author of the study. "Our results show that secondary prevention, or lowering cholesterol levels after being diagnosed with heart disease, has an even greater impact." For people with existing heart disease, the NCEP guidelines suggest low density lipoprotein (LDL) cholesterol levels should be at 100 milligrams per deciliter of blood (mg/dL). For people without known heart disease, the guidelines suggest LDL levels should be at 130 mg/dL or 160 mg/dL, depending on the status of risk factors such as diabetes, smoking habits, and age.

Between 60 to 75 percent of the epidemiologic benefits derived from lowering cholesterol levels, assuming full compliance of the guidelines, were projected to affect people already diagnosed with heart disease, said Goldman. Lower levels of cholesterol in this population were projected to result in 60 percent of the overall decrease of heart attacks and
'"/>

Contact: Rebecca Sladek Nowlis
RSNowlis@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
1-Sep-1999


Page: 1 2

Related medicine news :

1. Cholesterol under-treated in high-risk women in managed care study
2. Cholesterol-lowering drug may also reduce risk of blood clots
3. Cholesterol-lowering drug may slow Alzheimers progression
4. Cholesterol-lowering medications may reduce risk of glaucoma
5. Cholesterol levels fluctuate with the seasons
6. Cholesterol-lowering drugs may help stroke patients get well
7. Cholesterol drugs may lower risk for mental impairment after stroke
8. Cholesterol drug increases pain-free walking distance
9. Cholesterol drug helps heart failure patients without high cholesterol
10. Cholesterol drug could lead to new therapy for multiple sclerosis
11. Cholesterol fighting drugs may also have protective effects against multiple sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cholesterol guidelines can reduce recurrent heart problems

(Date:6/19/2013)... treating stroke victims has been "time equals brain." That,s because ... a drug that dissolves the stroke-causing blood clot can make ... or lost. , But specific information has been ... drug known as a tissue plasminogen activator, or tPA ... most common type of stroke. , Now, a ...
(Date:6/19/2013)... Loyola University Chicago Niehoff School of Nursing researcher has ... Vitamin D can improve mood in women with diabetes ... whether vitamin D supplementation can reduce blood pressure and ... is from the National Institute of Nursing Research at ... M. Penckofer, PhD, RN and colleagues hypothesize that women ...
(Date:6/19/2013)... 19, 2013 AquaPrint Solutions in Thomson, IL ... Grub with a newly-designed Harley Davidson motorcycle gas tank. A ... Solutions with an idea of taking a split tank motorcycle ... and transforming it into a work of art. , ... Grub several toilet seats that had been dipped in a ...
(Date:6/19/2013)... FL (PRWEB) June 19, 2013 Fit Body ... Andrea Laing recently held a charity boot camp in order ... fibrosis. The fitness boot camp franchise hosted the ... to 11 a.m. with 75 boot camp participants and collected ... charity boot camp marks the second fundraiser held for Orlando ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... their expanded BRCA1 and BRCA2 testing service , ... genes. Analysis is available individually, or as part of ... up to seventeen additional genes with known links to ... TP53, CDK4, STK11, SMAD4, BMPR1A, CDH1, MET, FH, FLCN, ...
Breaking Medicine News(10 mins):Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 3
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... Nektar Therapeutics (Nasdaq: NKTR ) today announced ... for NKTR-181, a first-in-class, opioid analgesic molecule with ... rate of entry is designed to reduce the euphoria that ... opioid analgesics. 1 In the study data being presented ... "drug liking" and "feeling high" scores and had highly statistically ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
Cached News: